机构：[1]Lab of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[2]Division of Gastroenterology and Hepatology, National Healthy Commission (NHC) Key Laboratory of Digestive Diseases, State Key Laboratory for Oncogenes and Related Genes, Renji Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai Institute of Digestive Disease, Shanghai, China.[3]State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Air Force Military Medical University, Xi'an, China.首都医科大学附属北京友谊医院[4]Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States.
This work was supported by the National Nature Science Fund
of China (82170623, 81730016), Pinnacle Research Award from the
American Association for the Study of Liver Diseases, Gilead
Research Award and Translational Research Award from
Regenerative Medicine Minnesota to Enis Kostallari.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类|2 区医学
小类|2 区免疫学
最新[2023]版：
大类|2 区医学
小类|2 区免疫学
第一作者：
第一作者机构：[1]Lab of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Guo Yangkun,Ma Xiong,Nie Yongzhan,et al.Editorial: Hepatic immune response underlying liver cirrhosis and portal hypertension[J].Frontiers in immunology.2023,14:1174562.doi:10.3389/fimmu.2023.1174562.
APA：
Guo Yangkun,Ma Xiong,Nie Yongzhan,Kostallari Enis&Gao Jinhang.(2023).Editorial: Hepatic immune response underlying liver cirrhosis and portal hypertension.Frontiers in immunology,14,
MLA：
Guo Yangkun,et al."Editorial: Hepatic immune response underlying liver cirrhosis and portal hypertension".Frontiers in immunology 14.(2023):1174562
